The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades: Surveillance Epidemiology and End Results Data
Abstract
PURPOSE: The US population-based cancer registry Surveillance, Epidemiology, and End Results (SEER) database provides an opportunity to evaluate the incidence and survival rates of Ewing sarcoma (ES) for the past 3 decades. This analysis reflects trends for the diagnosis of localized versus metastatic disease and changes in ES survival in a setting of wide-ranging cancer care institutions across the United States, which is expected to be different from clinical trials published to date. MATERIALS/METHODS: Data from the SEER public-access database were reviewed for the diagnosis of ES of the bone among patients of 1 to 19 years of age between 1973 and 2004. Age-adjusted incidence was analyzed for the entire group and for localized and metastatic disease separately over the past 3 decades. Actuarial survival rates were examined for 3 intervals: 1973 to 1982, 1983 to 1992, and 1993 to 2004. RESULTS: The overall incidence of ES seemed to remain unchanged with an average of 2.93 cases/1,000,000 reported annually between 1973 and 2004. The proportion of patients with distant metastasis among all ES cases remained in the 26% to 28% range, whereas the percent of localized cases slightly increased from 57% in 1973 to 1982 to 67% in 1993 to 2004 and the proportion of unstaged cases decreased from 17% to 5%. The 5-year survival of localized disease increased from 44% in the first study decade to 68% in the period after 1993, whereas 5-year survival of metastatic disease increased from 16% to 39%. The corresponding 10-year survival increased from 39% to 63% for localized disease and from 16% to 32% for metastatic ES. CONCLUSIONS: The incidence of ES has not increased appreciably over the last 30 years. A marked decrease in the proportion of unstaged cases may be reflective of diagnostic improvement or changes in reporting. There is a clear improvement in survival for both localized and metastatic disease. Poorer outcome of metastatic patients still warrants intensification of therapy, which is currently being tested in several ongoing trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Cotterill, S. J., Ahrens, S., Paulussen, M., Jürgens, H. F., Voûte, P. A., Gadner, H., & Craft, A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3108 · Cited by 1,040
Clark, A. N. G., Mankikar, G. D., & Gray, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91280-5 · Cited by 697
The surveillance, epidemiology, and end results program: a national resource.
Hankey, B. F., Ries, L. A. G., & Edwards, B. K. (1999) · PubMed · Cited by 594
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1818 · Cited by 445
Jürgens, H., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voûte, T., Winkelmann, W., Winkler, K., et al. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m · Cited by 417
Burgert, E. O., Nesbit, M. E., Garnsey, L. A., Gehan, E. A., Herrmann, J., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., & Thomas, P. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1514 · Cited by 380
Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies
Paulussen, M., Ahrens, S., Burdach, S., Craft, A., Dockhorn-Dworniczak, B., Dunst, J., Fröhlich, B., Winkelmann, W., Zoubek, A., & Jürgens, H. (1998) · Annals of Oncology · doi:10.1023/a:1008208511815 · Cited by 317
Cited by
Childhood and adolescent cancer statistics, 2014
Ward, E., DeSantis, C., Robbins, A., Kohler, B., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21219 · Cited by 2,412
Balamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
Brohl, A. S., Solomon, D. A., Chang, W., Wang, J., Song, Y., Sindiri, S., Patidar, R., Hurd, L., Chen, L., Shern, J. F., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004475 · Cited by 435
Risk of recurrence and survival after relapse in patients with Ewing sarcoma
Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23040 · Cited by 315
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 305
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Murphey, M. D., Senchak, L. T., Mambalam, P. K., Logie, C. I., Klassen-Fischer, M. K., & Kransdorf, M. J. (2013) · RadioGraphics · doi:10.1148/rg.333135005 · Cited by 293
Jawad, M. U., Cheung, M. C., Min, E. S., Schneiderbauer, M. M., Koniaris, L. G., & Scully, S. P. (2009) · Cancer · doi:10.1002/cncr.24388 · Cited by 281
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Charan, M., Dravid, P., Cam, M., Audino, A., Gross, A. C., Arnold, M. A., Roberts, R. D., Cripe, T. P., Pertsemlidis, A., Houghton, P. J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32743 · Cited by 59
“However long-term outcomes in patients with metastatic, relapsed or treatment-refractory EWS are dismal, with survival rates <20%.(2) Consequently, new therapies for this disease are critically needed.”
BackgroundScarborough, J. A., McClure, E., Anderson, P., Dhawan, A., Durmaz, A., Lessnick, S. L., Hitomi, M., & Scott, J. G. (2020) · iScience · doi:10.1016/j.isci.2020.101293 · Cited by 38
Metadata
- Authors
- Esiashvili, N., Goodman, M., & Marcus, R. B.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2008-06
- Volume
- 30
- Issue
- 6
- Pages
- 425-430
- ISSN
- 1077-4114 (ISSN-L)
- OpenAlex
- W2072909107
- Cited by
- 582
- References
- 19
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.